Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01856595 · ClinicalTrials.gov registry record · Phase 1
PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients
A Phase 1 study of Diabetes Mellitus, Type 2, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
- 3
- Study locations
NCT01856595 is a Phase 1 study of Diabetes Mellitus, Type 2 that has completed, run by Pfizer. The registered enrollment target is 117 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT01856595, a Phase 1 study of Diabetes Mellitus, Type 2, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of PF-06291874 in Type 2 Diabetes patients.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PF-06291874
Study Locations (3)
California
- Anaheim Clinical Trials - Anaheim
- Profil Institute for Clinical Research, Inc. - Chula Vista
Florida
- MRA Clinical Research, LLC - South Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2013-05-13 |
| Est. Completion | 2014-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01856595
The ClinicalTrials.gov registry entry for NCT01856595 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01856595 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Florida.
Frequently Asked Questions
What is clinical trial NCT01856595 about?
NCT01856595 is a clinical study titled "PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients". The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of PF-06291874 in Type 2 Diabetes patients.
What is the current status of trial NCT01856595?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2013-05-13. Estimated completion is 2014-03-01.
What conditions does trial NCT01856595 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT01856595?
The interventions under investigation include: Placebo (DRUG), PF-06291874 (DRUG).
Who is sponsoring clinical trial NCT01856595?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01856595 being conducted?
This trial has 3 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)
RECRUITING · Phase 1
-
Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans
ACTIVE NOT RECRUITING · Phase 1
-
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
ACTIVE NOT RECRUITING · Phase 1
-
A Family Dyad-focused Diabetes Self-Management Intervention for African American Adults
ACTIVE NOT RECRUITING · Phase 1
-
Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.